X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs CIPLA - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA CIPLA SANOFI INDIA/
CIPLA
 
P/E (TTM) x 29.9 43.5 68.6% View Chart
P/BV x 5.3 3.6 147.0% View Chart
Dividend Yield % 1.7 0.4 478.1%  

Financials

 SANOFI INDIA   CIPLA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
CIPLA
Mar-17
SANOFI INDIA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs4,560622 733.2%   
Low Rs4,400458 960.1%   
Sales per share (Unadj.) Rs1,028.5181.9 565.6%  
Earnings per share (Unadj.) Rs129.012.9 1,002.0%  
Cash flow per share (Unadj.) Rs186.029.3 634.4%  
Dividends per share (Unadj.) Rs68.002.00 3,400.0%  
Dividend yield (eoy) %1.50.4 409.9%  
Book value per share (Unadj.) Rs753.6155.7 484.1%  
Shares outstanding (eoy) m23.03804.51 2.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.43.0 146.7%   
Avg P/E ratio x34.742.0 82.8%  
P/CF ratio (eoy) x24.118.4 130.7%  
Price / Book Value ratio x5.93.5 171.4%  
Dividend payout %52.715.5 339.3%   
Avg Mkt Cap Rs m103,174434,516 23.7%   
No. of employees `0003.623.0 15.7%   
Total wages/salary Rs m3,59226,338 13.6%   
Avg. sales/employee Rs Th6,537.76,349.1 103.0%   
Avg. wages/employee Rs Th991.41,143.0 86.7%   
Avg. net profit/employee Rs Th819.8449.3 182.4%   
INCOME DATA
Net Sales Rs m23,686146,302 16.2%  
Other income Rs m7082,287 31.0%   
Total revenues Rs m24,394148,589 16.4%   
Gross profit Rs m5,28124,758 21.3%  
Depreciation Rs m1,31313,229 9.9%   
Interest Rs m151,594 0.9%   
Profit before tax Rs m4,66112,222 38.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6911,798 94.1%   
Profit after tax Rs m2,97010,354 28.7%  
Gross profit margin %22.316.9 131.8%  
Effective tax rate %36.314.7 246.7%   
Net profit margin %12.57.1 177.2%  
BALANCE SHEET DATA
Current assets Rs m15,67387,370 17.9%   
Current liabilities Rs m6,67833,081 20.2%   
Net working cap to sales %38.037.1 102.3%  
Current ratio x2.32.6 88.9%  
Inventory Days Days7687 87.4%  
Debtors Days Days2262 35.8%  
Net fixed assets Rs m8,098111,567 7.3%   
Share capital Rs m2301,609 14.3%   
"Free" reserves Rs m17,088123,645 13.8%   
Net worth Rs m17,356125,254 13.9%   
Long term debt Rs m036,454 0.0%   
Total assets Rs m25,400209,532 12.1%  
Interest coverage x311.78.7 3,596.3%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.90.7 133.6%   
Return on assets %11.85.7 206.1%  
Return on equity %17.18.3 207.0%  
Return on capital %26.98.5 317.0%  
Exports to sales %24.534.2 71.6%   
Imports to sales %28.08.3 335.4%   
Exports (fob) Rs m5,80150,050 11.6%   
Imports (cif) Rs m6,62712,203 54.3%   
Fx inflow Rs m7,14551,066 14.0%   
Fx outflow Rs m6,84617,678 38.7%   
Net fx Rs m29933,388 0.9%   
CASH FLOW
From Operations Rs m3,22623,824 13.5%  
From Investments Rs m-1,555-13,127 11.8%  
From Financial Activity Rs m-1,818-13,239 13.7%  
Net Cashflow Rs m-147-2,478 5.9%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 60.4 20.8 290.4%  
Indian inst/Mut Fund % 14.4 12.2 118.0%  
FIIs % 14.6 23.7 61.6%  
ADR/GDR % 0.0 1.1 -  
Free float % 10.5 26.2 40.1%  
Shareholders   15,184 161,166 9.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   ALKEM LABORATORIES  PLETHICO PHARMA  WOCKHARDT LTD.  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Red; Auto Stocks Witness Selling(01:30 pm)

After opening the day flat, share markets in India continued to witness selling pressure and are currently trading in red. Sectoral indices are trading on a mixed note with stocks in the metals sector.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Aug 21, 2017 03:37 PM

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 5-YR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS